The whole-genome landscape of medulloblastoma subtypes
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Current therapies for medulloblastoma, a highly malignant childhood brain tumour, impose debilitating effects on the developing child, and highlight the need for molecularly targeted treatments with reduced toxicity. Previous studies have been unable to identify the full spectrum of driver genes and molecular processes that operate in medulloblastoma subgroups. Here we analyse the somatic landscape across 491 sequenced medulloblastoma samples and the molecular heterogeneity among 1,256 epigenetically analysed cases, and identify subgroup-specific driver alterations that include previously undiscovered actionable targets. Driver mutations were confidently assigned to most patients belonging to Group 3 and Group 4 medulloblastoma subgroups, greatly enhancing previous knowledge. New molecular subtypes were differentially enriched for specific driver events, including hotspot in-frame insertions that target KBTBD4 and ‘enhancer hijacking’ events that activate PRDM6. Thus, the application of integrative genomics to an extensive cohort of clinical samples derived from a single childhood cancer entity revealed a series of cancer genes and biologically relevant subtype diversity that represent attractive therapeutic targets for the treatment of patients with medulloblastoma. Genomic analysis of 491 medulloblastoma samples, including methylation profiling of 1,256 cases, effectively assigns candidate drivers to most tumours across all molecular subgroups. Medulloblastomas are highly malignant brain tumours that develop during childhood. Paul Northcott and colleagues analysed the whole-genome sequences of 491 medulloblastomas in order to characterize the genomic landscape across tumours and identify new drivers and mutational signatures. Their integrative genomic analyses, including methylation profiling of 1,256 medulloblastomas, identifies subgroup-specific driver mutations and suggests additional tumour subtypes. The authors assign driver mutations to a high proportion of the less well characterized Group 3 and Group 4, which together contribute to more than 60% of all medulloblastomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The overlap observed between the G3 and G4 tumors with respect to MYC amplification supports the working hypothesis that these medulloblastomas are not easily separable in part because they originate from a shared cerebellar progenitor cell pool, with each group arising from arrest at different points along a developmental stage continuum (8, 23).”
From The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients (2025) · cites this paper as [8]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Methylation array–based classification studies have categorized the G3/G4-2, G3/G4-3, and G3/G4-4 molecular subgroups as G3; the G3/G4-1, G3/G4-5, and G3/G4-6 subgroups as a mix of G3 and G4; and the G3/G4-7 and G3/G4-8 subgroups as primarily G4 (8).”
From The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients (2025) · cites this paper as [8]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041 · cited 2×
“T 0) 42 .”
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
BEDTools: a flexible suite of utilities for comparing genomic features
Quinlan, A. R., & Hall, I. M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq033 · Cited by 27,437
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657 · cited 1×
“The relatively recent recognition of consensus MB subgroups has rapidly changed the way MB is studied in the research setting and how it is diagnosed and treated in the clinic 39 .”
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,621 · cited 1×
“The functional effect of the mutations was annotated using Annovar 43 and the variants were assessed for their confidence and split into somatic and non-somatic calls.”
Principal components analysis corrects for stratification in genome-wide association studies
Price, A. L., Patterson, N. J., Plenge, R. M., Weinblatt, M. E., Shadick, N. A., & Reich, D. (2006) · Nature Genetics · doi:10.1038/ng1847 · Cited by 10,248
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“…previously detected in MB 16 and has been linked with underlying BRCA1 and BRCA2 mutations in breast, aggressive prostate, and pancreatic cancers 16,17 , was unexpectedly observed in most of the patients with Group 3 and Group 4 MB, and a subset of patients with SHH MB. Additional…”
Self-citationComprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
dbSNP: the NCBI database of genetic variation
Sherry, S. T. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.308 · Cited by 7,502
Cited by
Items 401–500 of 998
Molecular Mechanisms and Targeted Therapies of Advanced Basal Cell Carcinoma
Hoashi, T., Kanda, N., & Saeki, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911968 · Cited by 22
“Gain-of-function mutations in the SMO gene (L412F, S533N, W535L, and R562Q) activate the GLI transcription network [36,39,41].”
BackgroundThree‐dimensional genome structure and function
Liu, H., Tsai, H., Yang, M., Li, G., Bian, Q., Ding, G., Wu, D., & Dai, J. (2023) · MedComm · doi:10.1002/mco2.326 · Cited by 31
Exploring the Molecular Complexity of Medulloblastoma: Implications for Diagnosis and Treatment
Rechberger, J. S., Toll, S. A., Vanbilloen, W. J. F., Daniels, D. J., & Khatua, S. (2023) · Diagnostics · doi:10.3390/diagnostics13142398 · Cited by 21
“Interestingly, this alteration is disproportionally increased in SHH medulloblastoma and present in almost 19% of the subgroup [24].”
BackgroundSeq-ing the SINEs of central nervous system tumors in cerebrospinal fluid
Douville, C. B., Curtis, S., Summers, M., Azad, T. D., Rincón-Torroella, J., Wang, Y., Mattox, A. K., Avigdor, B. E., Dudley, J. C., Materi, J. D., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101148 · Cited by 21
“In some clinical settings such as pediatric patients, Real-CSF could act as a stand-alone test given the relative paucity of somatic mutations in many brain cancers of childhood.(36,37)”
BackgroundPitolli, C., Marini, A., Guerra, M., Pieraccioli, M., Marabitti, V., Palluzzi, F., Giacò, L., Tamburrini, G., Cecconi, F., Nazio, F., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02790-2 · Cited by 19
“We also analyzed the Pfister’s dataset [40, 41], in which the non-WNT/non-SHH MB patients ( n = 167) were classi - fied in eight different subtypes (I to VIII) according to the WHO 2021 Classification of Brain Tumours [42].”
MethodKats, I., Simovic-Lorenz, M., Schreiber, H. S., Sant, P., Mallm, J., Körber, V., Li, A., Velmurugan, P., Heuer, S., Kües, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54709-w · Cited by 20
“7D, Supplementary Data 3 – 4).”
InfluentialSelf-citationAn autocrine ActivinB mechanism drives TGFβ/Activin signaling in Group 3 medulloblastoma
Morabito, M., Larcher, M., Cavalli, F. M. G., Foray, C., Forget, A., Mirabal-Ortega, L., Andrianteranagna, M. J. D. D., Druillennec, S., Garancher, A., Masliah‐Planchon, J., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809830 · Cited by 19
“Thus, Group 3 can be subdivided into 2–3 different subtypes according to the different studies (Cavalli et al, 2017a; Northcott et al, 2017; Schwalbe et al, 2017).”
BackgroundMethodInfluentialSelf-citationGihawi, A., Rallapalli, G., Hurst, R., Cooper, C. S., Leggett, R. M., & Brewer, D. S. (2019) · Genome biology · doi:10.1186/s13059-019-1819-8 · Cited by 20
The Non-coding Side of Medulloblastoma
Laneve, P., & Caffarelli, E. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00275 · Cited by 19
“Gene mutations are rare in this group, and only four genes, namely, Smarca4, Kbtbd4, Ctdneo1, and Kmt2d, are mutated in 5% of cases (Northcott et al., 2017).”
BackgroundInfluentialVEGFC negatively regulates the growth and aggressiveness of medulloblastoma cells
Penco-Campillo, M., Comoglio, Y., Morel, Á. J. F., Hanna, R. A., Durivault, J., Leloire, M., Mejias, B., Pagnuzzi, M., Morot, A., Burel‐Vandenbos, F., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-01306-4 · Cited by 19
Qiu, B., Kline, C., & Mueller, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.674596 · Cited by 19
Whole-genome sequencing of extrachromosomal circular DNA of cerebrospinal fluid of medulloblastoma
Zhu, Y., Liu, Z., Guo, Y., Li, S., Qu, Y., Dai, L., Chen, Y., Ning, W., Zhang, H., & Ma, L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.934159 · Cited by 18
“After the new addition of molecular biological markers in the 2016 edition of the World Health Organization (WHO) CNS tumor classification (6), genetic testing plays an important role in the staging and treatment of MB, including CTNNB for the WNT group (57), TP53 for the SHH group (58), MYC or MYCN for group 3 (59),…”
MethodClinical and pre-clinical utility of genomics in medulloblastoma
Nör, C., & Ramaswamy, V. (2018) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2018.1503536 · Cited by 17
“ber aberrations, driver events, and outcomes [14,16].”
BackgroundInfluentialSelf-citationPreclinical efficacy of ribavirin in SHH and group 3 medulloblastoma
Huq, S., Kannapadi, N. V., Casaos, J., Lott, T., Felder, R., Serra, R., Gorelick, N. L., Ruiz-Cardozo, M. A., Ding, A. S., Cecia, A. F., et al. (2021) · Journal of Neurosurgery Pediatrics · doi:10.3171/2020.8.peds20561 · Cited by 18
Mo, J., Liu, F., Sun, X., Huang, H., Tan, K., Zhao, X., Li, R., Jiang, W., Sui, Y., Chen, X., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3186 · Cited by 23
Marabitti, V., Giansanti, M., Mitri, F. D., Gatto, F., Mastronuzzi, A., & Nazio, F. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1007641 · Cited by 28
“Despite the role of NOTCH signaling in MB initiation, a recent analysis showed that NOTCH ligands and receptors are strongly associated with poor survival across MB patients, and NOTCH is most activated in both SHH and Group 3 samples (Northcott et al., 2017).”
ResultKCTD1 is a new modulator of the KCASH family of Hedgehog suppressors
Fiore, A. D., Bellardinelli, S., Pirone, L., Russo, R., Angrisani, A., Terriaca, G., Bowen, M., Bordin, F., Besharat, Z. M., Canettieri, G., et al. (2023) · Neoplasia · doi:10.1016/j.neo.2023.100926 · Cited by 16
Yuan, M., Mahmud, I., Katsushima, K., Joshi, K., Saulnier, O., Pokhrel, R., Lee, B., Liyanage, W., Kunhiraman, H., Stapleton, S. L., et al. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01684-w · Cited by 17
“…aim, molecular analyses have subdivided MB into at least four principal molecular groups—WNT ‐ activated, SHH-activated, Group 3, and Group 4 [28, 34]—which differ in their underlying genetic alterations, clinical features, and treatment, with patients categorized into non-WNT sub-groups having…”
BackgroundSelf-citationA MYCN-driven de-differentiation profile identifies a subgroup of aggressive retinoblastoma
Ryl, T., Afanasyeva, E. A., Hartmann, T., Schwermer, M., Schneider, M., Schröder, C., Wagemanns, M., Bister, A., Kanber, D., Steenpaß, L., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06596-6 · Cited by 22
Self-citationChromatin remodeling defects in pediatric brain tumors
Κλώνου, Α., Spiliotakopoulou, D., Themistocleous, M. S., Piperi, C., & Papavassiliou, A. G. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.04.08 · Cited by 17
“Apart of lysine methyltransferases, lysine acetyltransferases (HATs) are also involved in brain development and they are linked to poor survival such as the downregulation of H4K16 HAT, hMOF (50).”
BackgroundInfluentialInTAD: chromosome conformation guided analysis of enhancer target genes
Okonechnikov, K., Erkek, S., Korbel, J. O., Pfister, S. M., & Chávez, L. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-2655-2 · Cited by 15
Self-citationMiele, E., Pò, A., Mastronuzzi, A., Carai, A., Besharat, Z. M., Pediconi, N., Abballe, L., Catanzaro, G., Sabato, C., Smaele, E. D., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12800 · Cited by 17
“High-throughput analyses have identified at least four subgroups of MB—WNT (Wingless)-driven MBs, SHH (Sonic hedgehog)-driven MBs, G3 (Group 3) MBs, G4 (Group 4) MBs [1-5].”
BackgroundSelf-citationNaeem, A., Harish, V., Coste, S., Parasido, E. M., Choudhry, M. U., Kromer, L. F., Ihemelandu, C., Petricoin, E. F., Pierobon, M., Noon, M. S., et al. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0277 · Cited by 15
Molecular Targeted Therapies: Time for a Paradigm Shift in Medulloblastoma Treatment?
Gatto, L., Franceschi, E., Tosoni, A., Nunno, V. D., Bartolini, S., & Brandes, A. A. (2022) · Cancers · doi:10.3390/cancers14020333 · Cited by 19
“As in group 3 MB, amplifications in MYC and CDK6 can be considered driver events in group 4 tumors [90]; furthermore, recently, the homeobox transcription factor Lmx1A has been identified as an important transcriptional regulator in this subgroup [91].”
BackgroundWang, R., Guan, W., Qiao, M., Zhang, Y., Zhang, M., Wang, K., Wang, Y., & Wang, L. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.153995 · Cited by 16
Landscaping the epigenetic landscape of cancer
Aranda‐Anzaldo, A., & Dent, M. A. R. (2018) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2018.06.005 · Cited by 21
Wells, M. F., Salick, M. R., Piccioni, F., Guss, E. J., Mitchell, J. M., Worringer, K. A., Raymond, J. J., Kommineni, S., Chan, K., Ho, D. J., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/476440 · Cited by 15
“Our genomewide fitness screen produced a ranked list of genetic contributors to SNaP proliferation, including known tumor suppressor genes TSC2, which is a causative factor in tuberous sclerosis (The European Chromosome 16 Tuberous Sclerosis Consortium, 1993), and PTEN, which is a known inhibitor of the PI3K/AKT pathw…”
BackgroundZhang, Y., Chen, F., & Creighton, C. J. (2021) · BMC Bioinformatics · doi:10.1186/s12859-021-04072-0 · Cited by 17
Drug Resistance in Medulloblastoma Is Driven by YB-1, ABCB1 and a Seven-Gene Drug Signature
Taylor, L., Wade, P., Johnson, J. E. C., Aldighieri, M., Morlando, S., Leva, G. D., Kerr, I. D., & Coyle, B. (2023) · Cancers · doi:10.3390/cancers15041086 · Cited by 18
“As little is known regarding the functional role of YB-1 in medulloblastoma, YB1 gene expression was first studied across a published human medulloblastoma cohort comprising >200 samples [16].”
BackgroundDisruption of regulatory domains and novel transcripts as disease‐causing mechanisms
Allou, L., & Mundlos, S. (2023) · BioEssays · doi:10.1002/bies.202300010 · Cited by 16
Surviving the hunger games: Metabolic reprogramming in medulloblastoma
Manfreda, L., Rampazzo, E., Persano, L., Viola, G., & Bortolozzi, R. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115697 · Cited by 15
Rahmani, E. S., Lawarde, A., Lingasamy, P., Moreno, S. V., Salumets, A., & Modhukur, V. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1233657 · Cited by 19
PRMT5 as a Potential Therapeutic Target in MYC-Amplified Medulloblastoma
Kumar, D., Jain, S., Coulter, D. W., Joshi, S. S., & Chaturvedi, N. K. (2023) · Cancers · doi:10.3390/cancers15245855 · Cited by 17
Targeting DNA Methylation Machinery in Pediatric Solid Tumors
Cristalli, C., & Scotlandi, K. (2024) · Cells · doi:10.3390/cells13141209 · Cited by 16
“…as: group 1 WNT-MB and group 2 Sonic Hedgehog (SHH)-MB, which are characterized by the constitutive active signaling of WNT and SHH, respectively; and group 3 and group 4, which are characterized by a preponderance of somatic copy number aberrations (SCNAs) and structural variants (SVs) [103].”
BackgroundKolekar, P. S., Balagopal, V., Dong, L., Liu, Y., Foy, S. G., Tran, Q., Mulder, H. L., Huskey, A. L. W., Plyler, E. M., Liang, Z., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1063 · Cited by 17
Self-citationProteogenomic characterization of skull-base chordoma
Zhang, Q., Xu, Z., Han, R., Wang, Y., Ye, Z., Zhu, J., Cai, Y., Zhang, F., Zhao, J., Yao, B., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52285-7 · Cited by 17
Advances in Diagnostic Immunohistochemistry for Primary Tumors of the Central Nervous System
Meredith, D. M. (2019) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000225 · Cited by 17
Korshunov, A., Okonechnikov, K., Sahm, F., Ryzhova, M. V., Stichel, D., Schrimpf, D., Ghasemi, D. R., Pajtler, K. W., Antonelli, M., Donofrio, V., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02102-z · Cited by 16
Self-citationMini‐symposium in medulloblastoma genomics in the modern molecular era
Ellison, D. W. (2020) · Brain Pathology · doi:10.1111/bpa.12838 · Cited by 15
“However, group 3 and group 4 tumors show some overlap on methylome profiling and, with sufficient tumors in the analysis, now break out into subgroups (2,10,18).”
BackgroundAlbert, T., Interlandi, M., Sill, M., Graf, M., Moreno, N., Menck, K., Rohlmann, A., Melcher, V., Korbanka, S., zu Hörste, G. M., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa254 · Cited by 24
Self-citationMedulloblastoma in Adults: Cytogenetic Phenotypes Identify Prognostic Subgroups
Goschzik, T., Muehlen, A. Z., Doerner, E., Waha, A., Friedrich, C., Hau, P., & Pietsch, T. (2021) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlab020 · Cited by 16
Rhabdomyosarcoma: How Advanced Molecular Methods Are Shaping the Diagnostic and Therapeutic Paradigm
Giannikopoulos, P., & Parham, D. M. (2021) · Pediatric and Developmental Pathology · doi:10.1177/10935266211013621 · Cited by 15
Shen, C. J., & Terezakis, S. A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.679701 · Cited by 22
“With standard treatments, the WNT subgroup is most favorable, with >90% 5-year PFS, followed by intermediate outcomes in the SHH and Group 4 subgroups (5-year PFS of 70-80%), and poor outcomes for Group 3 (5-year PFS of 50-60%) (8, 114, 130).”
BackgroundAMPK attenuates SHH subgroup medulloblastoma growth and metastasis by inhibiting NF-κB activation
Cai, J., Wang, Y., Wang, X., Ai, Z., Li, T., Pu, X., Yang, X., Yao, Y., He, J., Cheng, S. Y., et al. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-00963-2 · Cited by 15
Weidenbusch, B., Richter, G. H. S., Kesper, M. S., Guggemoos, M., Gall, K., Prexler, C., Kazantsev, I. V., Sipol, A. A., Lindner, L. H., Nathrath, M., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25087 · Cited by 18
“These technologies have led to the identification of molecular disease subclasses not previously recognized [24].”
BackgroundSelf-citationGarner, E. F., Stafman, L. L., Williams, A. P., Aye, J. M., Goolsby, C. D., Atigadda, V. R., Moore, B. P., Nan, L., Stewart, J. E., Hjelmeland, A. B., et al. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2950-1 · Cited by 15
Use case driven evaluation of open databases for pediatric cancer research
Jeanquartier, F., Jean-Quartier, C., & Holzinger, A. (2019) · BioData Mining · doi:10.1186/s13040-018-0190-8 · Cited by 16
“Table 3 lists the average top ten mutated genes within pediatric glioma from the selected databases of PedcBioPortal & cBioPortal, ICGC Data Portal and Pecan.”
MethodInfluentialInvolvement of Heparan Sulfate and Heparanase in Neural Development and Pathogenesis of Brain Tumors
Xiong, A., Spyrou, A., & Forsberg‐Nilsson, K. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-34521-1_14 · Cited by 17
Luo, Z., Dong, X., Yu, J., Xia, Y., Berry, K., Rao, R., Xu, L., Xue, P., Chen, T., Lin, Y., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.634056 · Cited by 16
Qiu, R., Wu, J., Gudenas, B. L., Northcott, P. A., Wechsler‐Reya, R. J., & Lü, Q. (2021) · Communications Biology · doi:10.1038/s42003-021-02075-4 · Cited by 18
Self-citationDelaidelli, A., Dunham, C., Santi, M., Negri, G. L., Triscott, J., Zheludkova, O., Голанов, А. В., Ryzhova, M., Okonechnikov, K., Schrimpf, D., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2057 · Cited by 15
“org Clin Cancer Res; 28(1) January 1, 2022 119”
BackgroundInfluentialSelf-citationExcess Wnt in neurological disease
Pascual, D. M., Rizi, D. J., Kaur, H., & Marcogliese, P. C. (2025) · Biochemical Journal · doi:10.1042/bcj20240265 · Cited by 18
Pediatric versus Adult Medulloblastoma: Towards a Definition That Goes beyond Age
Wooley, J. R., & Peñas-Prado, M. (2021) · Cancers · doi:10.3390/cancers13246313 · Cited by 17
Sreenivasan, L., Li, L. V., Leclair, P., & Lim, C. J. (2022) · Cells · doi:10.3390/cells11030381 · Cited by 18
Molecular and clinicopathologic characteristics of CNS embryonal tumors with BRD4::LEUTX fusion
Andreiuolo, F. D. M., Ferrone, C. K., Rajan, S., Perry, A., Güney, E., Cham, E. M., Giannini, C., Toland, A. M. S., Willard, N., de Souza, A. S., et al. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01746-7 · Cited by 14
“A third case was found in a series of medulloblastoma, where re-evaluation using version 12 of the Heidelberg classifier showed a match to CNS embryonal tumor with BRD4::LEUTX fusion [7].”
BackgroundMethodPRDM6 promotes medulloblastoma by repressing chromatin accessibility and altering gene expression
Schmidt, C., Cohen, S., Gudenas, B. L., Husain, S., Carlson, A., Westelman, S., Wang, L., Phillips, J. J., Northcott, P. A., Weiss, W. A., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-66811-6 · Cited by 18
“Because a subset of Group 4 medulloblastomas shows high expression of PRDM6 in conjunction with amplification of the MYCN oncogene 1,4 , we decided to investigate potential synergies between PRDM6 and MYCN expression on tumor development from NES cells.”
Self-citationSebo, D. J., Ali, I., Fetsko, A. R., Trimbach, A. A., & Taylor, M. R. (2025) · Scientific Reports · doi:10.1038/s41598-025-85784-8 · Cited by 16
“For example, Wnt-medulloblastoma, driven by activating mutations in β-catenin 31 , form highly abnormal vessels that possess fenestrations and lack BBB properties 32 .”
Self-citationConcurrent IDH1 and SMARCB1 Mutations in Pediatric Medulloblastoma: A Case Report
El‐Ayadi, M., Égervári, K., Merkler, D., McKee, T., Gumy‐Pause, F., Stichel, D., Capper, D., Pietsch, T., Ansari, M., & von Bueren, A. O. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00398 · Cited by 15
“Interestingly, a recent analysis of 491 sequenced MB samples identified six IDH1-R132C mutations with five of them in SHH activated MB (4).”
BackgroundResultSelf-citationYeo, K. K., Margol, A., Kennedy, R. J., Hung, L. T., Robison, N. J., Dhall, G., & Asgharzadeh, S. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03307-8 · Cited by 15
Preclinical Models of Craniospinal Irradiation for Medulloblastoma
Stripay, J. L., Merchant, T. E., Roussel, M. F., & Tinkle, C. L. (2020) · Cancers · doi:10.3390/cancers12010133 · Cited by 15
Asmar, A. J., Beck, D. B., & Werner, A. A. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112300 · Cited by 15
Disruption of topologically associating domains by structural variations in tetraploid cottons
Long, Y., Liu, Z., Wang, P., Yang, H., Wang, Y., Zhang, S., Zhang, X., & Wang, M. (2021) · Genomics · doi:10.1016/j.ygeno.2021.07.023 · Cited by 15
Molecular testing for adolescent and young adult central nervous system tumors: A Canadian guideline
Lim-Fat, M. J., MacDonald, M., Lapointe, S., Climans, S., Cacciotti, C., Chahal, M., Perreault, S., Tsang, D. S., Gao, A. F., Yip, S. S. F., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.960509 · Cited by 17
Self-citationEpigenetics and immune cells in medulloblastoma
Gorini, F., Miceli, M., Antonellis, P. D., Amente, S., Zollo, M., & Ferrucci, V. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1135404 · Cited by 17
“8:1 male: female ratio, and no differences in incidence across ethnicities (Ezzat et al., 2016; Northcott et al., 2017; Northcott et al., 2019).”
BackgroundMethodResultInfluentialStock, A., Mynarek, M., Pietsch, T., Pfister, S. M., Clifford, S. C., Goschzik, T., Sturm, D., Schwalbe, E. C., Hicks, D., Rutkowski, S., et al. (2019) · American Journal of Neuroradiology · doi:10.3174/ajnr.a6286 · Cited by 13
Self-citationMolecularly Targeted Agents in the Therapy of Pediatric Brain Tumors
Bornhorst, M., & Hwang, E. I. (2019) · Pediatric Drugs · doi:10.1007/s40272-019-00369-z · Cited by 14
Medulloblastoma: “Onset of the molecular era”
Dhanyamraju, P. K., Patel, T., & Dovat, S. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05971-w · Cited by 16
“…SHH comes from the constitutive activation of the sonic hedgehog (SHH) signaling pathway in this subgroup of MBs. Amplification of GLI-1/2 , mutations in SMO leading to gain of function, and perturbations in SUFU, PTCH1/2 which leads to loss of function are primary causes for SHH driven MBs [21].”
BackgroundYao, Y., Wang, Y., Yang, F., Wang, C., Mao, M., Gai, Q., He, J., Qin, Y., Yao, X., Lan, X., et al. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13835 · Cited by 15
Rao, H., Zhang, H., Zou, Y., Ma, P., Huang, T., Yuan, H., Zhou, J., Wan, L., Li, Q., Huang, S., et al. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1248755 · Cited by 18
“In addition, certain breakpoints of SVs may disrupt haploinsuf fi cient genes or their regulatory elements, placing the carriers at risk for neurodevelopmental or other clinical diseases (Schluth-Bolard et al., 2013; Northcott et al., 2014; Nilsson et al., 2017; Northcott et al., 2017).”
Self-citationMechanistic insights into medulloblastoma relapse
Peterson, K. D., Turos‐Cabal, M., Salvador, A., Palomo-Caturla, I., Howell, A. J., Vieira, M. E., Greiner, S. M., Barnoud, T., & Rodríguez‐Blanco, J. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108673 · Cited by 20
Smirnov, P., Przybilla, M. J., Simovic-Lorenz, M., Parra, R. G., Sušak, H., Ratnaparkhe, M., Wong, J., Körber, V., Mallm, J., Philippos, G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54547-w · Cited by 22
“Of note, these molecular processes were in part consistent with but mostly distinct from the changes identi fi ed when assessing differential expression between CT and non-CT tumours using bulk RNA-seq (46 fresh frozen 39 and 173 FFPE 40,41 , Supplementary Fig.”
Self-citationOLIG2 mediates a rare targetable stem cell fate transition in sonic hedgehog medulloblastoma
Desai, K., Wanggou, S., Luis, E., Whetstone, H., Yu, C., Vanner, R. J., Selvadurai, H. J., Lee, L., Vijay, J., Jaramillo, J. E., et al. (2025) · Nature Communications · doi:10.1038/s41467-024-54858-y · Cited by 17
Preclinical Modeling of Image-Guided Craniospinal Irradiation for Very-High-Risk Medulloblastoma
Smith, S. M. C., Bianski, B. M., Orr, B. A., Harknett, G., Onar‐Thomas, A., Gilbertson, R. J., Merchant, T. E., Roussel, M. F., & Tinkle, C. L. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.10.015 · Cited by 16
“Medulloblastoma (MB), the most common malignant pediatric brain tumor, is molecularly classified into 4 major subgroups: WNT, Sonic Hedgehog (SHH), Group 3 (G3), and Group 4 (G4) (1).”
BackgroundInhibition of Rho-Associated Kinase Suppresses Medulloblastoma Growth
Dyberg, C. H., Andonova, T., Olsen, T. K., Brodin, B. A., Kool, M., Kogner, P., Johnsen, J. I., & Wickström, M. (2019) · Cancers · doi:10.3390/cancers12010073 · Cited by 16
“These subgroups exhibit specific molecular drivers and are associated with different clinical features and outcomes [1,2].”
BackgroundSelf-citationConstruction and Validation of a 13-Gene Signature for Prognosis Prediction in Medulloblastoma
Li, C., Zou, H., Xiong, Z., Xiong, Y., Miyagishima, D. F., Wanggou, S., & Li, X. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00429 · Cited by 15
Epigenetic mechanisms in paediatric brain tumours: regulators lose control
Badodi, S., & Marino, S. (2022) · Biochemical Society Transactions · doi:10.1042/bst20201227 · Cited by 13
Groves, A. P., Clymer, J. R., & Filbin, M. G. (2022) · Pharmaceuticals · doi:10.3390/ph15060665 · Cited by 13
Nanomedicines and cell-based therapies for embryonal tumors of the nervous system
Moukhtari, S. H. E., Garbayo, E., Fernández‐Teijeiro, A., Rodríguez‐Nogales, C., Couvreur, P., & Blanco‐Prieto, M. J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.06.010 · Cited by 14
PRC2 Heterogeneity Drives Tumor Growth in Medulloblastoma
Yi, J., Kim, B., Shi, X., Zhan, X., Lu, Q. R., Xuan, Z., & Wu, J. I. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4313 · Cited by 16
Katsushima, K., Pokhrel, R., Mahmud, I., Yuan, M., Murad, R., Baral, P., Zhou, R., Chapagain, P. P., Garrett, T. J., Stapleton, S. L., et al. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01521-0 · Cited by 14
GRK2 promotes growth of medulloblastoma cells and protects them from chemotherapy-induced apoptosis
Pathania, A. S., Ren, X., Mahdi, M. Y., Shackleford, G. M., & Erdreich‐Epstein, A. (2019) · Scientific Reports · doi:10.1038/s41598-019-50157-5 · Cited by 16
Johann, P. D. (2020) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12616 · Cited by 18
Peñas-Prado, M., Theeler, B. J., Cordeiro, B., Dunkel, I. J., Hau, P., Mahajan, A., Robinson, G. W., Willmarth, N. E., Aboud, O., Aldape, K., et al. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa097 · Cited by 14
Self-citationThe landscape of extrachromosomal circular DNA in medulloblastomaPreprint
Chapman, O. S., Luebeck, J., Wani, S., Tiwari, A., Pagadala, M. S., Wang, S., Larson, J. D., Lange, J. T., Wong, I. T.-L., Dehkordi, S. R., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.18.464907 · Cited by 16
Self-citationHussein, O., Rayan, M., Matarid, T. R., Elkhalifa, D. H., Abunada, H. H., Therachiyil, L., Khalil, A. A., Shahab Uddin, M. S., Maccalli, C., & Korashy, H. M. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03514-4 · Cited by 16
“To address these limitations, single-cell RNA sequencing and spatial transcrip-tomics are now being increasingly employed to allow a more sophisticated understanding of CSCs and intra-and inter-tumor heterogeneity [36, 37].”
Wang, Q., Xin, X., Dai, Q., Sun, M., Chen, J., Mostafavi, E., Shen, Y., & Li, X. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108527 · Cited by 15
Drivers Underlying Metastasis and Relapse in Medulloblastoma and Targeting Strategies
Holmberg, K. O., Borgenvik, A., Zhao, M., Giraud, G., & Swartling, F. J. (2024) · Cancers · doi:10.3390/cancers16091752 · Cited by 18
ZIC1 is a context-dependent medulloblastoma driver in the rhombic lip
Lee, J. J. Y., Tao, R., You, Z., Haldipur, P., Erickson, A. W., Farooq, H., Hendriske, L. D., Abeysundara, N., Richman, C. M., Wang, E. Y., et al. (2025) · Nature Genetics · doi:10.1038/s41588-024-02014-z · Cited by 13
“Please see the Supplementary Information for full lists of the reagents, resources and bioinformatics tools used for the study (Supplementary Tables 1–16).”
InfluentialSelf-citationMedulloblastoma: Challenges and advances in treatment and research
Martirosian, V., & Neman, J. (2018) · Cancer Reports · doi:10.1002/cnr2.1146 · Cited by 13
An ABC Transporter Drives Medulloblastoma Pathogenesis by Regulating Sonic Hedgehog Signaling
Wijaya, J., Vo, B. T., Liu, J., Xu, B., Wu, G., Wang, Y., Peng, J., Zhang, J., Janke, L. J., Orr, B. A., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2054 · Cited by 14
“alterations typically found in human SHH-MB (42).”
Self-citationRestoration of miR-193a expression is tumor-suppressive in MYC amplified Group 3 medulloblastoma
Bharambe, H. S., Joshi, A. A., Yogi, K., Kazi, S., & Shirsat, N. V. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00942-5 · Cited by 12
Vitale, A. M., Santonocito, R., Vergilio, G., Marino, A., Campanella, C., de Macario, E. C., Bucchieri, F., Macario, A. J. L., & Bavisotto, C. C. (2020) · Applied Sciences · doi:10.3390/app10196961 · Cited by 14
Surgical management of posterior fossa medulloblastoma in children: The Lyon experience
Grassiot, B., Beuriat, P.-A., Rocco, F. D., Leblond, P., Faure‐Conter, C., Szathmári, A., & Mottolèse, C. (2021) · Neurochirurgie · doi:10.1016/j.neuchi.2021.01.003 · Cited by 12
Korshunov, A., Okonechnikov, K., Stichel, D., Ryzhova, M. V., Schrimpf, D., Sahm, F., Sievers, P., Absalyamova, O. V., Zheludkova, O., Голанов, А. В., et al. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab031 · Cited by 12
Self-citationNeuropathology of Pediatric Brain Tumors: A Concise Review
Cole, B. (2021) · Neurosurgery · doi:10.1093/neuros/nyab182 · Cited by 15
“The remainder of medulloblastomas are group 3 and 4 tumors, which collectively are grouped as non-WNT/non-SHH group in the current edition of theWHO classification system; additional molecular testing such as methylation profiling or nanoString testing is necessary to reliably distinguish group 3 from group 4.(7,21,22…”
BackgroundNoncoding RNAs in pediatric brain tumors: Molecular functions and pathological implications
Chen, S., Deng, X., Sheng, H., Rong, Y., Zheng, Y., Zhang, Y., & Lin, J. J. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.07.024 · Cited by 14
MAPK15 Controls Hedgehog Signaling in Medulloblastoma Cells by Regulating Primary Ciliogenesis
Pietrobono, S., Franci, L., Imperatore, F., Zanini, C., Stecca, B. A., & Chiariello, M. (2021) · Cancers · doi:10.3390/cancers13194903 · Cited by 12
Ljungblad, L. M., Bergqvist, F., Tümmler, C., Madawala, S. R. P., Olsen, T. K., Andonova, T., Jakobsson, P., Johnsen, J. I., Picková, J., Strandvik, B., et al. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120394 · Cited by 12
Korshunov, A., Okonechnikov, K., Stichel, D., Schrimpf, D., Delaidelli, A., Tonn, S., Mynarek, M., Sievers, P., Sahm, F., Jones, D., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02460-1 · Cited by 13
“Numerous reports have indicated the presence of significant heterogeneity among Grp 3 MB, describing various and partly overlapping subgroups/subtypes differing both from clinical and molecular standpoints [3, 21, 28, 29].”
BackgroundMethodResultInfluentialSelf-citationKorshunov, A., Sahm, F., Okonechnikov, K., Ryzhova, M. V., Stichel, D., Schrimpf, D., Casalini, B., Sievers, P., Meyer, J., Zheludkova, O., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01981-6 · Cited by 13
Self-citation
Metadata
- Authors
- Northcott, P. A., Buchhalter, I., Morrissy, A. S., Hovestadt, V., Weischenfeldt, J., Ehrenberger, T., Gröbner, S., Segura-Wang, M., Zichner, T., Rudneva, V. A., Warnatz, H.-J., Sidiropoulos, N., Phillips, A. H., Schumacher, S., Kleinheinz, K., Waszak, S. M., Erkek, S., Jones, D. T. W., Worst, B. C., Kool, M., Zapatka, M., Jäger, N., Chavez, L., Hutter, B., Bieg, M., Paramasivam, N., Heinold, M., Gu, Z., Ishaque, N., Jäger-Schmidt, C., Imbusch, C. D., Jugold, A., Hübschmann, D., Risch, T., Amstislavskiy, V., Gonzalez, F. G. R., Weber, U. D., Wolf, S., Robinson, G. W., Zhou, X., Wu, G., Finkelstein, D., Liu, Y., Cavalli, F. M. G., Luu, B., Ramaswamy, V., Wu, X., Koster, J., Ryzhova, M., Cho, Y.-J., Pomeroy, S. L., Herold-Mende, C., Schuhmann, M., Ebinger, M., Liau, L. M., Mora, J., McLendon, R. E., Jabado, N., Kumabe, T., Chuah, E., Ma, Y., Moore, R. A., Mungall, A. J., Mungall, K. L., Thiessen, N., Tse, K., Wong, T., Jones, S. J. M., Witt, O., Milde, T., Von Deimling, A., Capper, D., Korshunov, A., Yaspo, M.-L., Kriwacki, R., Gajjar, A., Zhang, J., Beroukhim, R., Fraenkel, E., Korbel, J. O., Brors, B., Schlesner, M., Eils, R., Marra, M. A., Pfister, S. M., Taylor, M. D., & Lichter, P.
- Affiliations
- St. Jude Children's Research Hospital (US)
- German Cancer Research Center (DE)
- Hospital for Sick Children (CA)
- University of Copenhagen (DK)
- Massachusetts Institute of Technology (US)
- European Molecular Biology Laboratory (DE)
- Max Planck Institute for Molecular Genetics (DE)
- Broad Institute (US)
- Burdenko Neurosurgery Institute (RU)
- Oregon Health & Science University (US)
- Boston Children's Hospital (US)
- Universitätsklinikum Tübingen (DE)
- University Children's Hospital Tübingen (DE)
- University of California, Los Angeles (US)
- Hospital Sant Joan de Déu Barcelona (ES)
- Duke University (US)
- McGill University (CA)
- Kitasato University Hospital (JP)
- BC Cancer Agency (CA)
- University Hospital Heidelberg (DE)
- Corresponding author
- Pfister, Stefan M.
- Taylor, Michael D.
- Lichter, Peter
- ORCID
- Northcott, Paul A.
- Buchhalter, Ivo
- Morrissy, A. Sorana
- Hovestadt, Volker
- Weischenfeldt, Joachim
- Zichner, Thomas
- Rudneva, Vasilisa A.
- Warnatz, Hans-Jörg
- Sidiropoulos, Nikos
- Phillips, Aaron H.
- Schumacher, Steven
- Kleinheinz, Kortine
- Waszak, Sebastian M.
- Erkek, Serap
- Jones, David T. W.
- Kool, Marcel
- Zapatka, Marc
- Jäger, Natalie
- Hutter, Barbara
- Bieg, Matthias
- Paramasivam, Nagarajan
- Gu, Zuguang
- Ishaque, Naveed
- Imbusch, Charles D.
- Hübschmann, Daniel
- Amstislavskiy, Vyacheslav
- Robinson, Giles W.
- Zhou, Xin
- Wu, Gang
- Finkelstein, David
- Liu, Yanling
- Cavalli, Florence M. G.
- Ramaswamy, Vijay
- Wu, Xiaochong
- Ryzhova, Marina
- Cho, Yoon-Jae
- Pomeroy, Scott L.
- Schuhmann, Martin
- Ebinger, Martin
- Liau, Linda M.
- Mora, Jaume
- McLendon, Roger E.
- Jabado, Nada
- Kumabe, Toshihiro
- Moore, Richard A.
- Mungall, Andrew J.
- Wong, Tina
- Jones, Steven J. M.
- Witt, Olaf
- Milde, Till
- Capper, David
- Korshunov, Andrey
- Yaspo, Marie-Laure
- Kriwacki, Richard
- Gajjar, Amar
- Zhang, Jinghui
- Beroukhim, Rameen
- Fraenkel, Ernest
- Korbel, Jan O.
- Brors, Benedikt
- Schlesner, Matthias
- Eils, Roland
- Marra, Marco A.
- Pfister, Stefan M.
- Taylor, Michael D.
- Lichter, Peter
- Venue
- Nature
- Published
- 2017-07
- Volume
- 547
- Issue
- 7663
- Pages
- 311-317
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5905700
- OpenAlex
- W2737542366
- Cited by
- 1,112
- References
- 66
- Citations by year
- 2026: 63 · 2025: 132 · 2024: 125 · 2023: 154 · 2022: 142 · 2021: 148 · 2020: 120 · 2019: 120 · 2018: 94 · 2017: 12
- FWCI
- 54.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor, 19 d)
- Locations
- Nature (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Max Planck Digital Library (submittedVersion, other-oa)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- MPG.PuRe (Max Planck Society) (submittedVersion, cc-by)
- OPUS (Augsburg University) (submittedVersion, cc-by)
- Funders
- Alexander and Margaret Stewart Trust
- Pediatric Brain Tumor Foundation (R01CA159859)
- Deutsches Krebsforschungszentrum
- Genome Canada (R01CA159859)
- Children's Hospital Foundation
- Ontario Institute for Cancer Research
- American Lebanese Syrian Associated Charities
- Government of Ontario
- Genome British Columbia (R01CA159859)
- Canada Research Chairs
- Brain Tumour Charity (GN-000356)
- Bundesministerium für Bildung und Forschung (01KU1505E, 01KU1201A, 01KU1505A)
- Terry Fox Research Institute (R01CA159859)
- Deutsche Krebshilfe (109252)
- Hospital for Sick Children
- Stichting Kinderen Kankervrij
- BC Cancer Foundation (FDN-143288)
- Brain Tumour Research
- National Institutes of Health
- Heidelberger Zentrum für Personalisierte Onkologie Deutsches Krebsforschungszentrum In Der Helmholtz-Gemeinschaft
- Garron Family Cancer Centre
- National Cancer Institute (R01CA148699, R01CA109467, R01CA159859)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- medulloblastoma, molecular subtypes, driver mutations, somatic mutations, mutational signatures, enhancer hijacking, in-frame insertion, DNA methylation, Group 3 medulloblastoma, Group 4 medulloblastoma, therapeutic target, childhood brain tumours, integrative genomics
- MeSH terms
- Whole Genome Sequencing, Carrier Proteins, DNA Mutational Analysis, Epistasis, Genetic, Humans, Medulloblastoma, Muscle Proteins, Mutation, Oncogenes, Transcription Factors, Cohort Studies, Genome, Human, DNA Methylation, Genomics, Wnt Proteins, Molecular Targeted Therapy, Carcinogenesis, Datasets as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.